Vivos Therapeutics, Inc. (VVOS)

SEC filing

Vivos Therapeutics, Inc.

VVOS · CIK 1716166

4 · Sep 18, 2026 · Director, Chief Executive Officer Huntsman Ronald Kirk acquired 171.82K shares at $0.582/share ($99,999)

Director, Chief Executive Officer Huntsman Ronald Kirk acquired 171.82K shares at $0.582/share ($99,999)

xslF345X06/ownership.xml

xslF345X06/ownership.xmlSEC.gov

Graphics and non-inline formats (not embedded below).